Skip to main content

Table 2 Univariate associations with CKD documentation

From: Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort study

Baseline Characteristics With CKD Documentation
N = 1478 (14.40)
(% or SD)
Without CKD Documentation
N = 8788 (85.6)
(% or SD)
Odds Ratio (with vs without CKD documentation) P value
Mean age (continuous) 62.84 (13.51) 63.10 (13.41) NA 0.4829
Mean eGFR* (continuous) 38.66 (13.04) 50.52 (8.41) NA < .0001
Men 876 (21.08) 3279 (78.92) 2.44 (2.18-2.73) < .0001
Hypertension 1397 (17.65) 6519 (82.35) 6.00 (4.77-7.54) < .0001
Diabetes 565 (22.53) 1943 (77.47) 2.18 (1.94-2.44) < .0001
eGFR 50-59 346 (5.90) 5522 (94.10) 1.00 (Referent) -
eGFR 40-49 372 (14.35) 2221 (85.65) 2.67 (2.29-3.12) -
eGFR 30-49 362 (31.70) 780 (68.30) 7.40 (6.27-8.73) -
eGFR 20-39 252 (50.14) 205 (44.86) 19.61 (15.84-24.3) -
eGFR 10-19 146 (70.87) 60 (29.13) 38.83 (28.21-53.46) < 0.0001**
Coronary artery disease 293 (21.95) 1042 (78.05) 1.83 (1.59-2.12) < .0001
Chronic heart failure 216 (28.80) 534 (71.20) 2.64 (2.23-3.13) < .0001
Cerebrovascular disease 38 (23.31) 125 (76.69) 1.82 (1.26- 2.64) 0.0011
Peripheral artery disease 151 (30.82) 339 (69.18) 2.83 (2.32-3.46) < .0001
ACEI use 300 (20.00) 1200 (80.00) 1.61 (1.39-1.85) < .0001
ARB use 34 (21.79) 122 (78.21) 1.67 (1.13-2.45) 0.0080
Statin use 248 (17.13) 1200 (82.87) 1.27 (1.09- 1.48) 0.0014
NSAID use 122 (10.06) 1091 (89.94) 0.63 (0.52- 0.77) < .0001
  1. *eGFR in ml/min/1.73 m2, ** P value for trend, NA not appropriate